
CLAIMS

~~1. A pharmaceutical formulation comprising a sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate salt of Formula 1 below.~~

~~[Formula I]~~




~~2. The pharmaceutical formulation for oral administration according to claim 1, characterized in that the pharmaceutical formulation is in the form of a tablet or capsule.~~

1~~3~~. A pharmaceutical ~~formulation~~capsule for oral administration comprising a sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate salt of Formula 1 below and an enteric coating comprising an enteric polymer,

wherein the enteric polymer comprises a methacrylic acid-methyl methacrylate 1:1 copolymer and a methacrylic acid-methyl methacrylate 1:2 copolymer in a weight ratio of 1:1.

[Formula I]



~~4. The pharmaceutical formulation according to claim 3, characterized in that the enteric polymer is at least one selected from the group consisting of a methacrylic acid-methyl methacrylate copolymer, a methyl acrylate-methyl methacrylate-methacrylic acid copolymer, a methacrylic acid-ethyl acrylate copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethyl ethyl cellulose, and shellac.~~

~~5. The pharmaceutical formulation according to claim 3, characterized in that the enteric polymer is a methacrylic acid-methyl methacrylate copolymer, a methyl acrylate-methyl methacrylate-methacrylic acid copolymer, or a mixture thereof.~~

~~6. The pharmaceutical formulation according to claim 3, characterized in that the enteric polymer is a methacrylic acid-methyl methacrylate 1:1 copolymer, a methacrylic acid-methyl methacrylate 1:2 copolymer, or a mixture thereof.~~

~~7. The pharmaceutical formulation according to claim 3, characterized in that the enteric polymer is a methacrylic acid-methyl methacrylate 1:2 copolymer.~~

~~8. The pharmaceutical formulation according to claim 3, characterized in that the enteric polymer comprises a methacrylic acid-methyl methacrylate 1:1 copolymer and a methacrylic acid-methyl methacrylate 1:2 copolymer in a weight ratio of 1:1.~~

2~~9~~. The pharmaceutical ~~formulation~~ capsule according to claim 1~~3~~, characterized in that the pharmaceutical formulation comprises the enteric polymer in an amount of 10 to 300 parts by weight based on 100 parts by weight of the sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate salt.

3~~10~~. The pharmaceutical ~~formulation~~ capsule according to claim 1~~3~~, characterized in that the pharmaceutical formulation comprises the enteric polymer in an amount of 20 to 80 parts by weight based on 100 parts by weight of the sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate.

411. The pharmaceutical ~~formulation~~ capsule according to claim 1~~3~~, characterized in that the pharmaceutical formulation further comprises at least one additive selected from the group consisting of microcrystalline cellulose, mannitol, hydroxypropyl methylcellulose (HPMC), polyethylene oxide, sodium croscarmellose, crospovidone, ~~–~~polyoxyglyceride, magnesium aluminometasilicate, magnesium stearate, talc, and sodium starch glycolate.

512. The pharmaceutical ~~formulation~~ capsule according to claim 1~~3~~, characterized in that the pharmaceutical formulation further comprises at least one additive selected from the group consisting of magnesium stearate, sodium starch glycolate, talc, and triethyl citrate (TEC).

~~13. The pharmaceutical formulation according to claim 3, characterized in that the pharmaceutical formulation comprises a methacrylic acid-methyl methacrylate 1:2 copolymer as the enteric polymer, and further comprises hydroxypropyl methylcellulose (HPMC) and magnesium stearate.~~

614. The pharmaceutical ~~formulation~~ capsule according to claim 1~~3~~, characterized in that sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate is dissolved at pH 6.0 or higher.

715. The pharmaceutical ~~formulation~~ capsule according to claim 1~~3~~, characterized in that in the dissolution test at 37°C and 100 rpm according to the United States Pharmacopeia (USP) type 2 paddle method, 20% or less of sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate is dissolved in a pH 6.0 buffer for 1 hour, and 80% or more of sodium ~~–~~palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate is dissolved in a pH 7.4 buffer for 1 hour.